Skip to main content
Clinical Trials/NL-OMON36912
NL-OMON36912CompletedPhase 3

Prevention of radiation-induced parotid gland dysfunction by parotid-gland stem-cell sparing intensity-modulated radiotherapy (SCS-IMRT) - Parotid gland stem cell sparing radiotherapy

niversitair Medisch Centrum Groningen0 sites102 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
102

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Patients treated with planned curative primary radiotherapy for HNC, with or without chemotherapy or cetuximab meeting the following criteria:
  • - Squamous cell carcinoma originating from the mucosa of the head and neck area or nasofaryngeal carcinoma originating from the nasofarynx;
  • - The radiotherapy includes prophylactic or therapeutic irradiation of both sides of the neck (at least level II to IV);
  • - Age * 18 years;
  • - WHO performance 0-2;
  • - pre-treatment stimulated parotid gland saliva production >0.2 ml/min.

Exclusion Criteria

  • - Postoperative radiotherapy;
  • - Re-irradiation;
  • - Unilateral radiotherapy;
  • - Primary salivary gland tumours

Investigators

Similar Trials